Heart failure with reduced ejection fraction: a systematic review of clinical practice guidelines and recommendations
Abstract
Heart failure with reduced ejection fraction (HFrEF) accounts for over half of heart failure cases and its management is directed by international clinical practice guidelines. To evaluate current recommendations, we conducted a systematic review of guidelines on the diagnosis and management of HFrEF in adults. MEDLINE and EMBASE were searched on 10 November 2024 for publications within the past decade, and websites of relevant medical societies were reviewed. Twelve guidelines were identified, of which seven met predefined AGREE II criteria for methodological 'rigour of development' and were included in the final analysis. Across the selected guidelines, there was broad consensus on the prevention of heart failure, the definition of HFrEF, and the initial diagnostic approach. Recommended investigations included coronary CT angiography, cardiac magnetic resonance imaging, and invasive coronary angiography in selected patients. There was also agreement on the principles of pharmacological management, with consistent endorsement of foundational therapies such as renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors. However, key differences emerged regarding thresholds for serum natriuretic peptides, sequencing of RAAS inhibitors, and device-based therapies including implantable defibrillators in non-ischaemic HFrEF, cardiac resynchronization therapy, and indications for…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.